152 related articles for article (PubMed ID: 25597918)
1. The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy.
Oh KS; Lee JH; Yi KY; Lim CJ; Lee S; Park CH; Seo HW; Lee BH
Br J Pharmacol; 2015 May; 172(10):2618-33. PubMed ID: 25597918
[TBL] [Abstract][Full Text] [Related]
2. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
3. A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure.
Oh KS; Lee JH; Yi KY; Lim CJ; Park BK; Seo HW; Lee BH
Eur J Pharmacol; 2017 Mar; 799():94-102. PubMed ID: 28163023
[TBL] [Abstract][Full Text] [Related]
4. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.
Johns DG; Ao Z; Naselsky D; Herold CL; Maniscalco K; Sarov-Blat L; Steplewski K; Aiyar N; Douglas SA
Naunyn Schmiedebergs Arch Pharmacol; 2004 Oct; 370(4):238-50. PubMed ID: 15549273
[TBL] [Abstract][Full Text] [Related]
5. GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.
Behm DJ; Aiyar NV; Olzinski AR; McAtee JJ; Hilfiker MA; Dodson JW; Dowdell SE; Wang GZ; Goodman KB; Sehon CA; Harpel MR; Willette RN; Neeb MJ; Leach CA; Douglas SA
Br J Pharmacol; 2010 Sep; 161(1):207-28. PubMed ID: 20718751
[TBL] [Abstract][Full Text] [Related]
6. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
[TBL] [Abstract][Full Text] [Related]
7. Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy.
Kompa AR; Wang BH; Phrommintikul A; Ho PY; Kelly DJ; Behm DJ; Douglas SA; Krum H
Peptides; 2010 Aug; 31(8):1523-30. PubMed ID: 20452383
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
Clozel M; Binkert C; Birker-Robaczewska M; Boukhadra C; Ding SS; Fischli W; Hess P; Mathys B; Morrison K; Müller C; Müller C; Nayler O; Qiu C; Rey M; Scherz MW; Velker J; Weller T; Xi JF; Ziltener P
J Pharmacol Exp Ther; 2004 Oct; 311(1):204-12. PubMed ID: 15146030
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice.
Tandon R; Soni A; Singh RK; Sodhi R; Seth MK; Sinha S; Sahdev S; Dhage G; Das B; Dastidar SG; Shriumalla RK; Yonesu K; Marumoto S; Nagayama T
Eur J Pharmacol; 2020 Nov; 886():173391. PubMed ID: 32745605
[TBL] [Abstract][Full Text] [Related]
10. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.
Elshourbagy NA; Douglas SA; Shabon U; Harrison S; Duddy G; Sechler JL; Ao Z; Maleeff BE; Naselsky D; Disa J; Aiyar NV
Br J Pharmacol; 2002 May; 136(1):9-22. PubMed ID: 11976263
[TBL] [Abstract][Full Text] [Related]
11. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.
Herold CL; Behm DJ; Buckley PT; Foley JJ; Wixted WE; Sarau HM; Douglas SA
Br J Pharmacol; 2003 May; 139(2):203-7. PubMed ID: 12770925
[TBL] [Abstract][Full Text] [Related]
12. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
Douglas SA; Behm DJ; Aiyar NV; Naselsky D; Disa J; Brooks DP; Ohlstein EH; Gleason JG; Sarau HM; Foley JJ; Buckley PT; Schmidt DB; Wixted WE; Widdowson K; Riley G; Jin J; Gallagher TF; Schmidt SJ; Ridgers L; Christmann LT; Keenan RM; Knight SD; Dhanak D
Br J Pharmacol; 2005 Jul; 145(5):620-35. PubMed ID: 15852036
[TBL] [Abstract][Full Text] [Related]
13. The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts.
Dai HY; Kang WQ; Wang X; Yu XJ; Li ZH; Tang MX; Xu DL; Li CW; Zhang Y; Ge ZM
Regul Pept; 2007 Apr; 140(1-2):88-93. PubMed ID: 17188370
[TBL] [Abstract][Full Text] [Related]
14. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.
Tzanidis A; Hannan RD; Thomas WG; Onan D; Autelitano DJ; See F; Kelly DJ; Gilbert RE; Krum H
Circ Res; 2003 Aug; 93(3):246-53. PubMed ID: 12842917
[TBL] [Abstract][Full Text] [Related]
15. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.
Bousette N; Pottinger J; Ramli W; Ohlstein EH; Dhanak D; Douglas SA; Giaid A
Peptides; 2006 Nov; 27(11):2919-26. PubMed ID: 16919371
[TBL] [Abstract][Full Text] [Related]
16. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.
Behm DJ; McAtee JJ; Dodson JW; Neeb MJ; Fries HE; Evans CA; Hernandez RR; Hoffman KD; Harrison SM; Lai JM; Wu C; Aiyar NV; Ohlstein EH; Douglas SA
Br J Pharmacol; 2008 Oct; 155(3):374-86. PubMed ID: 18587423
[TBL] [Abstract][Full Text] [Related]
17. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol.
Zhang YG; Li YG; Liu BG; Wei RH; Wang DM; Tan XR; Bu DF; Pang YZ; Tang CS
Acta Pharmacol Sin; 2007 Jan; 28(1):36-43. PubMed ID: 17184580
[TBL] [Abstract][Full Text] [Related]
18. A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II-Induced Pressure Response in Mice.
Nishi M; Yonesu K; Tagawa H; Kato M; Marumoto S; Nagayama T
J Cardiovasc Pharmacol; 2019 Jan; 73(1):15-21. PubMed ID: 30608334
[TBL] [Abstract][Full Text] [Related]
19. Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.
Douglas SA; Naselsky D; Ao Z; Disa J; Herold CL; Lynch F; Aiyar NV
Br J Pharmacol; 2004 Jul; 142(6):921-32. PubMed ID: 15210573
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.
Behm DJ; Ao Z; Camarda V; Aiyar NV; Johns DG; Douglas SA
Eur J Pharmacol; 2005 Jun; 516(3):276-81. PubMed ID: 15975570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
